

# Contents

## Chapter I: Recent Developments of the Histamine Problem

### Section A: Pharmacological Actions

#### 1. Cardiovascular Actions of Histamine. B. M. ALTURA and S. HALEVY. With 3 Figures

I. Introduction . . . . .	1
II. Systemic Vascular Effects of Histamine . . . . .	2
A. Rat . . . . .	2
B. Guinea-Pig . . . . .	2
C. Rabbit . . . . .	3
D. Dog . . . . .	3
E. Cat . . . . .	3
F. Calf, Horse, and Sheep . . . . .	7
G. Man . . . . .	7
III. Cardiac Actions of Histamine . . . . .	7
A. Intact Animals . . . . .	11
1. Inotropic Action . . . . .	11
2. Chronotropic Action . . . . .	11
3. Dromotropic Action . . . . .	11
4. Cardiac Output . . . . .	11
B. Isolated Heart Preparations . . . . .	12
1. Inotropic Action . . . . .	12
2. Chronotropic Action . . . . .	12
3. Dromotropic Action . . . . .	12
4. Coronary Flow . . . . .	13
IV. Effects of Histamine on Regional Vasculatures . . . . .	13
A. Coronary . . . . .	13
B. Pulmonary Lung . . . . .	21
C. Splanchnic . . . . .	21
D. Liver-Portal . . . . .	22
E. Renal . . . . .	22
F. Musculo-Cutaneous . . . . .	22
G. Cerebral . . . . .	22
H. Miscellaneous . . . . .	22
V. Microcirculatory Actions of Histamine . . . . .	22
A. Direct In-Vivo Microcirculatory Actions of Histamine . . . . .	24
B. $H_1$ Versus $H_2$ -Receptors in Microcirculation . . . . .	25
C. Effects of Histamine on Vascular Permeability and Endothelial Cells . . . . .	26

VI. Isolated Vascular Smooth Muscle and Histamine . . . . .	27
VII. Conclusions . . . . .	29
References . . . . .	30

## **2. Histamine and Gastric Secretion. L.R. JOHNSON. With 7 Figures**

I. Introduction . . . . .	41
II. Historical Review . . . . .	41
III. Physiologic Evidence . . . . .	43
A. Histidine Decarboxylase Activation . . . . .	43
B. Histamine Release and Gastric Secretion . . . . .	46
IV. H <sub>2</sub> -Receptor Antagonists: Gastric Secretion and the Role of Histamine	49
V. Conclusions . . . . .	54
References . . . . .	55

## **Section B: Histamine Release**

### **1. On the General Problem of the Release of Histamine. A. GOTH**

I. Introduction . . . . .	57
II. The Noncytotoxic Nature of Histamine Secretion . . . . .	58
III. Histamine Release and Complement . . . . .	60
IV. The IgE Receptor . . . . .	60
V. Control Mechanisms of Histamine Release . . . . .	61
Cyclic Nucleotides and Histamine Release . . . . .	61
VI. Enhancers and Inhibitors of Histamine Release . . . . .	62
A. Enhancers of Histamine Release . . . . .	62
1. Phosphatidyl Serine . . . . .	63
2. Deuterium Oxide (D <sub>2</sub> O) . . . . .	63
3. Cholinergic Stimulation . . . . .	64
B. Inhibitors of Histamine Release . . . . .	64
1. The Role of Calcium in Histamine Release . . . . .	65
2. Desensitization . . . . .	66
VII. Histamine Release from Tissues and Platelets . . . . .	67
A. Histamine Release from Isolated Tissues and Organs . . . . .	67
B. Histamine Release from Platelets . . . . .	67
VIII. Concluding Remarks . . . . .	68
References . . . . .	69

### **2. The Mechanism of Histamine Release from Mast Cells. B. UVNÄS. With 9 Figures**

I. Introduction . . . . .	75
II. The Normal Mast Cells . . . . .	75
A. Morphology . . . . .	75
B. Contents . . . . .	78

III. The Degranulating Mast Cell . . . . .	78
A. Degranulating Agents . . . . .	78
B. Noncytotoxic Character of the Degranulation Process . . . . .	79
C. Electron-Microscopic Changes . . . . .	79
IV. Storage Properties of Basophil Granules . . . . .	82
A. Role of Heparin . . . . .	82
B. Role of Zinc . . . . .	83
C. Role of the Granule Protein-Heparin Complex . . . . .	84
V. Relationship Between Degranulation and Histamine Release . . . . .	87
References . . . . .	90

### **3. Metabolic Changes in Mast Cells Associated with Histamine Release.**

N. CHAKRAVARTY. With 8 Figures

I. Energy Dependence of Anaphylactic Histamine Release . . . . .	93
II. Energy Metabolism of Mast Cells . . . . .	95
III. Changes in Mast Cell Respiration in Relation to Histamine Release . . . . .	97
IV. Changes in Glucose Metabolism in Mast Cells Associated with Histamine Release . . . . .	98
V. Changes in Adenosine Triphosphate Content of Mast Cells Associated with Histamine Release . . . . .	101
VI. Conclusion . . . . .	105
References . . . . .	106

## **Section C: Metabolism and Excretion of Histamine**

### **1. Biogenesis of Histamine. R. W. SCHAYER**

I. Introduction . . . . .	109
II. Methods for Determination of Histidine Decarboxylase Activity of Mammalian Tissues . . . . .	109
III. Histamine Formation in vitro . . . . .	110
IV. Histamine Formation in vivo . . . . .	113
V. Inhibition of Histamine Formation in vitro . . . . .	115
VI. Inhibition of Histamine Formation in vivo . . . . .	117
VII. Histidine Decarboxylase Activation and Deactivation; Role of Protein and RNA Synthesis . . . . .	118
VIII. Effect of Hormones on Histamine Formation . . . . .	119
IX. Histamine Formation in Brain . . . . .	119
X. Histamine Formation and Antihistamines . . . . .	121
XI. Conclusion . . . . .	122
References . . . . .	122

## 2. Histamine Metabolism and Excretion. H. WETTERQVIST

I. Histamine Metabolism in Tissues . . . . .	132
II. Changes in Histamine Metabolism in Tissues . . . . .	133
III. Histamine Metabolism and Excretion in Animals . . . . .	134
A. Rat . . . . .	134
B. Mouse . . . . .	135
C. Guinea Pig . . . . .	135
D. Hamster . . . . .	136
E. Rabbit . . . . .	136
F. Sheep . . . . .	136
G. Goat . . . . .	136
H. Pig . . . . .	137
I. Cow . . . . .	137
J. Horse . . . . .	137
K. Cat . . . . .	137
L. Toad, Tortoise, Terrapin . . . . .	137
IV. Changes in Histamine Metabolism and Excretion in Animals . . . . .	137
V. Histamine Metabolism in Human Tissues . . . . .	139
VI. Histamine Metabolism and Excretion in Man . . . . .	139
VII. Changes in Histamine Metabolism and Excretion in Man . . . . .	140
VIII. Blood Diseases . . . . .	142
IX. Allergy . . . . .	142
X. Burns . . . . .	142
XI. Miscellaneous . . . . .	143
XII. Comments . . . . .	143
References . . . . .	143

## 3. The Enzymatic Isotopic Assay of Histamine. M.A.BEAVEN and Z.HORAKOVA. With 3 Figures

I. Introduction . . . . .	151
A. Principle of Isotope Derivative Dilution Assays . . . . .	151
B. Applications of Isotope Derivative Dilution Analysis in Biological Work . . . . .	152
C. Enzymatic Isotope Derivative Dilution Assays . . . . .	153
II. Double Isotope Assay (with $\beta$ - <sup>3</sup> H-Histamine as Internal Standard) . . . . .	154
A. Principle . . . . .	154
B. Chemicals . . . . .	154
C. Preparation of $\beta$ - <sup>3</sup> H-(side-chain label)-Histamine . . . . .	155
D. Preparation of Histamine-N-Methyltransferase . . . . .	155
E. Storage and Preparation of Samples for Analysis . . . . .	156
F. Reagents and Stock Solutions (in Order of Use) . . . . .	157
G. Incubation Procedure . . . . .	157
H. Extraction and Measurement of Labeled Methylhistamine . . . . .	158
I. Calculation . . . . .	159
J. Comments . . . . .	160

III. Single Isotope Microenzymatic Assay of Histamine . . . . .	161
A. Introduction . . . . .	161
B. Chemicals . . . . .	161
C. Reagents . . . . .	161
D. Procedure . . . . .	161
E. Calculation . . . . .	162
F. Comments . . . . .	162
IV. General Precautions to Be Observed with Enzymatic Assays of Histamine	162
A. Specificity of Assay . . . . .	162
B. Assay Blanks and Precision of Assay . . . . .	162
C. Extraction Procedure and Use of Unlabeled Methylhistamine as Carrier	163
D. Interference from Drugs and Tissue Constituents . . . . .	163
E. Importance of Purity of Labeled SAME . . . . .	164
V. Use of Enzymatic Assay in Measurement of Histamine, L-Histidine, and Histamine-Metabolizing Enzymes in Tissues . . . . .	164
A. Histamine . . . . .	164
B. Assay of Histidine . . . . .	169
C. Histidine Decarboxylase . . . . .	170
D. Assay of Histamine-N-Methyltransferase . . . . .	170
References . . . . .	171

## **Chapter II: Chemistry and Structure-Activity Relationships of Synthetic Anti-Histaminics**

### **Section A: Chemistry of Anti-H<sub>1</sub> Histamine Antagonists. A.F.CASY. With 2 Figures**

I. Introduction . . . . .	175
II. Chemical Types of H <sub>1</sub> -Antihistaminic Drugs . . . . .	179
A. Early Work . . . . .	179
B. Ethylenediamines . . . . .	179
C. Tertiary-aminoalkyl Ethers . . . . .	182
D. 1,2-Diaryl-4-Aminobutenes . . . . .	185
E. 1,1-Diaryl-3-Aminopropenes . . . . .	189
F. 3-Amino-1-Aryl-1-(2-Pyridyl)Propanes(Pheniramines) . . . . .	193
G. Phenothiazine Derivatives . . . . .	196
H. Further Tricyclic Derivatives . . . . .	198
I. Miscellaneous Types . . . . .	202
References . . . . .	207

### **Section B: Structure-Activity Relationships of H<sub>1</sub>-Receptor Antagonists.**

W.Th.NAUTA and R.F.REKKER. With 2 Figures

I. Introduction . . . . .	215
II. Compilation of the Most Important Structures with Anti-H <sub>1</sub> Activity. Classification of the Structures Considered and Review of Measured Anti-H <sub>1</sub> Activities . . . . .	216

III. Physical Properties and Anti-H <sub>1</sub> Activity . . . . .	227
A. Qualitative Drug Design Based on the Physical Properties of Structures . . . . .	227
1. Ionization Constants . . . . .	227
2. Solubilities . . . . .	227
3. Surface Properties . . . . .	228
4. Spectral Data . . . . .	228
5. Bond Stabilities . . . . .	229
6. Charge Localizations . . . . .	229
7. Dipole Moments . . . . .	230
B. Quantitative Design. The Hansch Approach . . . . .	231
1. Introduction . . . . .	231
2. The Hansch Approach Applied to a Series of Ring-Substituted Diphenhydramine Derivatives . . . . .	232
3. The Hansch Approach Applied to a Series of Diphenhydramines with the Nitrogen Atom Included in a Ring System . . . . .	232
4. The Activities of 1,1-Diaryl-3-Aminopropenes, and Some Related Compounds . . . . .	233
C. Some Features of Anti-H <sub>1</sub> Activity Connected with Stereospecificity. Conformational Preferences . . . . .	234
1. Anti-H <sub>1</sub> Activities of Structures with an Optically Active Center . . . . .	234
2. Anti-H <sub>1</sub> Activities of Cis-Trans Isometric Structures . . . . .	239
3. The Inclusion of Optically Active Structures into the Hansch Approach . . . . .	239
D. Integrated QSAR of H <sub>1</sub> -Receptor Antagonists . . . . .	240
IV. Conclusion . . . . .	245
References . . . . .	245

## Section C: Chemistry and Structure-Activity Relationships of H<sub>2</sub>-Receptor Antagonists.

C.R. GANELLIN. With 17 Figures

I. Introduction . . . . .	251
II. Development of H <sub>2</sub> -Receptor Antagonists . . . . .	253
A. The Search for an Antagonist . . . . .	253
B. Development of Burimamide . . . . .	256
C. Development of Metiamide . . . . .	260
D. Development of Cimetidine . . . . .	265
III. Chemical Constitution . . . . .	267
A. Introduction . . . . .	267
B. Burimamide and Metiamide . . . . .	267
C. Cimetidine . . . . .	274
IV. Chemical Mode of Action . . . . .	277
V. Pharmacokinetics . . . . .	280
A. Absorption and Distribution . . . . .	280
B. Metabolism and Elimination . . . . .	281

VI. Chemical Differentiation Between $H_1$ - and $H_2$ -Receptor Antagonists . . .	283
VII. Synthesis of Burimamide, Metiamide, and Cimetidine . . . . .	285
References . . . . .	287

### Chapter III: Mechanism of Action of Antihistaminics

#### Section A: Kinetics of Antagonist Action. M.ROCHA E SILVA. With 21 Figures

I. The Charnière Theory . . . . .	295
II. Applications of the Theory . . . . .	312
III. Appendix . . . . .	326
References . . . . .	329

#### Section B: Competitive and Noncompetitive Antagonism. FRANS G.VAN DEN BRINK and ERIC J.LIEN. With 11 Figures

I. Introduction . . . . .	333
II. Material and Methods . . . . .	334
A. Test Organs . . . . .	334
B. Affinity and Intrinsic Activity Values . . . . .	334
C. Test Substances . . . . .	335
III. Results and Discussion . . . . .	340
A. Closer Inspection of the Intrinsic Activity and Affinity Values in Table 1 . . . . .	340
1. Intrinsic Activity and Affinity Values of Partial Agonists . . . . .	340
2. $pA_2$ -Values Based on a Smaller Number of Animals than the Accompanying $pD'_2$ -Values, and Vice Versa . . . . .	341
B. The Interaction of Agonists and Competitive Antagonists with the Histamine Receptors; the Role of Additional Receptor Areas . . . . .	342
C. Competitive Antagonists and Their Affinity to the Metactoid Receptor . . . . .	345
1. The $pA_2/pD'_2$ -Ratios in the Histaminergic System . . . . .	345
2. The $pA_2/pD'_2$ -Ratios in the Cholinergic System . . . . .	349
3. Comparison of the $pD'_2$ -Values in the Histaminergic and the Cholinergic System . . . . .	350
D. Influence of Some Molecular Modifications on the Affinity Values . . . . .	351
1. The Influence of the Substitution of a Methyl Group to the Secondary N-Atom. The "Rule of Pfeiffer" . . . . .	351
2. The Influence of the Presence or Absence of an N-Atom in the Ring in the "Mimetic Moiety" (Pyridyl or Phenyl Ring) . . . . .	353
3. The Influence of Para-Substitution of a Cl-Atom at the Phenyl Ring in the N-phenyl-N-benzyl-ethylamine Group . . . . .	354
4. The Influence of Para-Substitution at the Phenyl Ring of N-(N'-phenyl-N'-benzyl- $\beta$ -aminoethyl)-N-methyl-{2-( $\beta$ -aminoethyl)-pyridine} . . . . .	355

E. Quantitative Structure-Activity Correlations of 2-( $\beta$ -aminoethyl)-pyridines . . . . .	360
F. Pitfalls in Structure-Activity Relationship Studies . . . . .	363
References . . . . .	366

### **Section C: Naturally Occuring Antihistaminics in Body Tissues. G. PELLETIER.**

With 1 Figure

I. Introduction . . . . .	369
II. Methods of Extraction of Antihistamine Activity . . . . .	370
General Considerations . . . . .	371
III. Methods of Assay of Natural Antihistamine Substance(s) (NAS) . . . . .	371
Units of Activity . . . . .	372
IV. Estimation of Antihistamine Activity in Mammals . . . . .	372
V. Modifications of Amount of NAS Present in Tissues and Fluids . . . . .	372
A. Elevation of NAS . . . . .	374
B. Diminution of NAS . . . . .	375
VI. Mechanism of Action of NAS . . . . .	375
VII. Physical and Chemical Aspects of NAS . . . . .	376
A. Molecular Weight . . . . .	376
B. Solubility . . . . .	376
C. Stability . . . . .	377
D. Chemical Structure . . . . .	377
VIII. Role of NAS . . . . .	377
References . . . . .	378

## **Chapter IV: Pharmacological Actions of Antihistaminics**

### **Section A: Bioassay of Antihistaminic Action. M.ROCHA E SILVA and A.ANTONIO.**

With 7 Figures

I. Introduction . . . . .	381
II. In Vitro Assays for Antihistaminics . . . . .	391
A. Assays on the Guinea Pig Ileum and Other Smooth Muscle Structures . . . . .	391
B. On the Schultz-Dale Reaction of the Sensitized Strips of the Guinea Pig Ileum and Uterus . . . . .	399
C. Bioassay of Antihistaminics on the Isolated Mammalian Heart . . . . .	400
D. Interrelations Between Antihistaminics and the Histamine( $H_1$ ) Receptors . . . . .	402
III. In Vivo Assays of Antihistaminics . . . . .	405
A. Protection Against the Lethal Effects of Histamine . . . . .	405
B. Protection Against Asthma (Bronchospasm) Produced by Inhalation of a Histamine Aerosol . . . . .	406



C. Protection of Sensitized Guinea Pigs Submitted to the Challenging Dose of the Antigen . . . . .	411
D. Atropine-like Effects of Antihistaminics . . . . .	413
E. Local Anesthetic Action of Antihistaminics . . . . .	417
F. Action on the Skin Vessels and on Vascular Permeability . . . . .	420
IV. Conclusions . . . . .	424
References . . . . .	425

## **Section B: Antianaphylactic and Antiallergic Effects. F. HAHN**

I. Introduction . . . . .	439
II. General Aspects of Antianaphylactic and Antiallergic Effects of Antihistaminics . . . . .	440
A. Receptor Specificity . . . . .	440
B. Potency of Antihistaminics . . . . .	441
C. Effect of Antihistaminics on Endogenously Released Histamine . . . . .	441
D. Nonspecific Effects of Antihistaminics . . . . .	442
III. Effects of Antihistaminics on Guinea Pig Anaphylaxis . . . . .	445
A. Systemic Shock . . . . .	445
1. Antilethal Effects . . . . .	445
2. Effect of Antihistaminics on Bronchospasm in vivo . . . . .	452
B. Action of Antihistaminics in Isolated Organs . . . . .	453
1. Lung and Trachea . . . . .	453
2. Isolated Gut . . . . .	455
3. Uterus . . . . .	456
4. Striated Muscle . . . . .	456
C. Heart Anaphylaxis . . . . .	456
D. Heart-Lung Preparation (HLP) . . . . .	461
E. Adrenals and Adrenergic System . . . . .	461
1. Role of Catecholamine Release in the Antianaphylactic Action of Antihistaminics on Acute Shock . . . . .	461
2. Protracted Shock and Adrenal Glands . . . . .	464
F. Action of Antihistaminics on Antigen Aerosols . . . . .	465
G. Action of Antihistaminics on Cutaneous Anaphylaxis . . . . .	466
H. Forssman Shock . . . . .	467
I. Miscellaneous . . . . .	468
IV. Anaphylaxis in Dogs . . . . .	469
V. Anaphylaxis in Rabbits . . . . .	470
VI. Anaphylaxis in Rats . . . . .	471
VII. Anaphylaxis in Mice . . . . .	474
VIII. Other Species . . . . .	475
Summary and Conclusions . . . . .	478
References . . . . .	480

**Section C: Antiinflammatory Effects.** C.G. Van ARMAN

I. Recent Work Involving H <sub>2</sub> -Receptors . . . . .	505
II. Effect of Antiinflammatory Drugs on the Interactions of Histamine with Other Possible Mediators of Inflammation . . . . .	506
III. Implications of Antiinflammatory Drugs for Elucidating Possible Roles of Histamine . . . . .	508
A. In Anaphylactic Shock . . . . .	508
B. In Allergy . . . . .	509
C. Responses of Tracheal Muscle . . . . .	509
IV. Inflammations in Which Antihistaminics Have Little or No Effect . . . . .	510
V. Evidence from Depletion Experiments . . . . .	510
References . . . . .	510

**Chapter V: Absorption, Distribution, Metabolism, and Elimination of Antihistamines.**

D.T. WITIAK and N.J. LEWIS

I. Early Studies of Antihistamine Distribution, Excretion, and Metabolism . . . . .	513
II. Diphenhydramine and Orphenadrine . . . . .	516
III. Tripeleennamine Metabolism . . . . .	523
IV. Cyclizine, Chlorcyclizine, and Related Compounds . . . . .	526
V. Chlorpheniramine and Brompheniramine . . . . .	532
VI. Chlorphenesin, Chlorphenesin Carbamate, and Related Phenoxo Propanediols . . . . .	535
VII. Perazine, Prochlorperazine, Trifluoperazine, and Fluphenazine . . . . .	537
VIII. Promethazine, Chlorpromazine, and Related Compounds . . . . .	538
IX. Cyproheptadine, Amitriptyline, Nortriptyline, and Protriptyline . . . . .	543
X. Doxepin . . . . .	546
XI. Hepzidine . . . . .	547
XII. Drug Metabolism and Enzyme Induction . . . . .	549
XIII. H <sub>2</sub> Histamine Antagonists . . . . .	552
References . . . . .	554

**Chapter VI: Therapeutic Action of Anti-Histaminics****Section A: Antihistaminics as Central Nervous System Depressants.** C.L. FAINGOLD.

With 1 Figure

I. Introduction . . . . .	561
II. Laboratory Studies . . . . .	561
A. Behavioral Studies . . . . .	562
B. Drug Interaction Studies . . . . .	562
C. EEG Studies . . . . .	562
III. Clinical Studies . . . . .	563
A. Ethylenediamine Agents . . . . .	563
B. Alkylamine Agents . . . . .	565

C. Piperazine Agents . . . . .	565
D. Phenothiazine Agents . . . . .	566
E. Aminoalkyl Ether Agents . . . . .	566
IV. Mechanism of Action . . . . .	567
References . . . . .	570

## **Section B. Circulatory Shock, Histamine and Antihistamines: Therapeutic Aspects.**

B.M.ALTURA and S.HALEVY

I. Introduction . . . . .	575
II. Vasoactive Agents: Use and Misuse in Low-Flow States . . . . .	577
III. Failure of Peripheral Vascular-Homeostatic Mechanisms . . . . .	580
IV. Vasoactive Mediators in Circulatory Shock . . . . .	581
V. Is Histamine the Mediator of the Shock Syndrome? . . . . .	584
VI. Plasma Histamine Levels in Man and Animals in Shock . . . . .	585
A. Hemorrhage . . . . .	586
B. Trauma . . . . .	587
C. Endotoxemia-Sepsis . . . . .	587
D. Burns-Scalding . . . . .	587
E. Anaphylactic Shock . . . . .	588
VII. Influence of Antihistamines on Survival after Circulatory Shock . . . . .	588
A. Histamine Shock . . . . .	589
B. Hemorrhage . . . . .	589
C. Trauma . . . . .	592
D. Endotoxemia-Sepsis . . . . .	593
E. Burns-Scalding . . . . .	593
F. Anaphylactic Shock . . . . .	594
VIII. Conclusions and Future Outlook for Antihistamine Therapy in Circulatory Shock and Low-Flow States . . . . .	594
References . . . . .	594

<b>Author Index . . . . .</b>	<b>603</b>
-------------------------------	------------

<b>Subject Index . . . . .</b>	<b>655</b>
--------------------------------	------------